Pluriomics receives a €3.2M grant under the Horizon 2020 SME instrument programme to advance cardiovascular drug discovery

Leiden, The Netherlands, June 16, 2016 – Pluriomics, an emerging Dutch/Belgian biotechnology company whose mission is to deliver innovative human cardiomyocyte assays for use in drug discovery & development, today announced it was awarded a prestigious EU SME instrument grant. This grant gives Pluriomics the opportunity to advance cardiovascular drug discovery, in order to reduce […]

READ MORE read more

Pluriomics CEO is a co-author of a new book entitled “Stem Cell-Derived Models in Toxicology”

Leiden, The Netherlands, December 2, 2016 –  Stefan Braam (Pluriomics CEO) and Gary Gintant (Abbvie) co-published a chapter in the “Stem Cell-Derived Models in Toxicology” book underlying the added value of Stem Cell-Derived Models for Safety and Toxicity Assessments. The promise of human, stem cell-derived models for safety and toxicity assessments remains great. Using such preparations, […]

READ MORE read more

News archive

SOT 56th Annual Meeting and ToxExpo

Location: Baltimore, Maryland, USA Date: March 12 – 16, 2017 Pluriomics will exhibit and present during the SOT 56th Annual Meeting and ToxExpo in Baltimore, USA The Society of Toxicology’s 56th annual meeting is a key networking event dedicated to toxicology. It features a broad range of stimulating lectures and presentations on scientific breakthroughs, important education and […]

READ MORE read more

ISSCR international symposium 2017

Location: Basel, Switzerland Date: February 27 – March 1, 2017 Pluriomics will be present at ISSCR international symposium 2017 in Basel, Switzerland This meeting organized by the International Society for Stem Cell Research (ISSCR), StemBANCC and the Basel Stem Cell Network for Translational Opportunities in Stem Cell Research will engage experts to present and to discuss […]

READ MORE read more

Events archive

About us

Pluriomics develops and commercializes fully functional, human iPSC-derived cardiomyocytes and provides high quality services for efficient and reliable safety pharmacology testing and cardiovascular drug efficacy screening.

Pluriomics, a leading expert in human cardiovascular stem cell technology, manufactures fully functional human iPSC derived cardiomyocytes (Pluricyte® Cardiomyocytes) using well-defined, serum-free medium that enhances the maturation and function of the cells. Pluriomics combines Pluricyte® Cardiomyocytes with innovative technologies to develop in-house cell-based assays with the objective to improve drug safety and efficacy screening.

Read more

Pluricyte® Cardiomyocyte Kit

Pluricyte® Cardiomyocyte Kit is developed and manufactured for use in drug discovery and development. The kit includes both Pluricyte® Cardiomyocytes and Pluricyte® Cardiomyocyte Medium (serum-free).

iView product information

Our solutions